Alector, Inc. (ALEC) — SEC Filings

Latest SEC filings for Alector, Inc. (ALEC), explained in plain English.

Sentiment Overview: 3 bearish, 27 neutral, 1 mixed

Recent Filings (31)

• Alector, Inc. Reports Director Changes and Compensation Updates — 8-K · 2025-12-12T00:00:00.000Z [neutral] Risk: low
  Alector, Inc. announced on December 10, 2025, changes related to its board of directors and executive compensation. Specifically, the company reported the depar
• Alector Narrows Q3 Loss Amid Revenue Drop, R&D Cuts — 10-Q · 2025-11-06T00:00:00.000Z [bearish] Risk: high
  Alector, Inc. (ALEC) reported a net loss of $34.667 million for the three months ended September 30, 2025, an improvement from the $42.220 million net loss in t
• Alector, Inc. Files 8-K: Operations, Exits, and Officer Changes — 8-K · 2025-10-21T00:00:00.000Z [neutral] Risk: medium
  Alector, Inc. filed an 8-K on October 21, 2025, reporting on events as of October 20, 2025. The filing covers results of operations, costs associated with exit
• Alector's Q2 Net Loss Widens to $70.5M Amid R&D Spend — 10-Q · 2025-08-07T00:00:00.000Z [bearish] Risk: high
  Alector, Inc. reported a net loss of $70.5 million for the quarter ended June 30, 2025, a significant increase from the $55.2 million net loss in the prior-year
• Alector, Inc. Files 8-K: Director/Officer Changes & More — 8-K · 2025-06-13T00:00:00.000Z [neutral] Risk: medium
  Alector, Inc. filed an 8-K on June 13, 2025, reporting events as of June 9, 2025. The filing covers the departure of directors, election of new directors, appoi
• Alector, Inc. Files Q1 2025 10-Q — 10-Q · 2025-05-08T00:00:00.000Z [neutral] Risk: medium
  Alector, Inc. filed its 10-Q for the period ending March 31, 2025. The company, focused on biological products, reported on its financial activities. Key financ
• Alector Inc. Executive Compensation Filing Details — DEF 14A · 2025-04-24T00:00:00.000Z [neutral] Risk: low
  Alector, Inc. filed a DEF 14A on April 24, 2025, detailing executive compensation and stock awards for the fiscal years ending December 31, 2020, 2021, 2022, 20
• Alector Appoints Dr. Arnon Rosenthal as CSO — 8-K · 2025-03-28T00:00:00.000Z [neutral] Risk: low
  Alector, Inc. announced on March 25, 2025, the appointment of Dr. Arnon Rosenthal as Chief Scientific Officer. Dr. Rosenthal, previously a Senior Vice President
• Alector, Inc. Reports Exit and Disposal Costs — 8-K · 2025-03-10T00:00:00.000Z [neutral] Risk: medium
  On March 7, 2025, Alector, Inc. filed an 8-K report detailing cost associated with exit or disposal activities. The filing does not specify the exact dollar amo
• 10-K Filing — 10-K · 2025-02-26T00:00:00.000Z [neutral]
• Alector Appoints Dr. Arnon Rosenthal as CSO — 8-K · 2025-01-10T00:00:00.000Z [neutral] Risk: medium
  On January 9, 2025, Alector, Inc. announced the appointment of Dr. Arnon Rosenthal as Chief Scientific Officer. Dr. Rosenthal brings extensive experience in neu
• SC 13G Filing — SC 13G · 2024-12-06T00:00:00.000Z [neutral]
• Alector, Inc. Files 8-K on Exit Costs and Disclosures — 8-K · 2024-11-25T00:00:00.000Z [neutral] Risk: medium
  On November 25, 2024, Alector, Inc. filed an 8-K report detailing cost associated with exit or disposal activities. The filing also included Regulation FD discl
• Alector, Inc. Files 8-K: Material Agreement and Financial Disclosures — 8-K · 2024-11-14T00:00:00.000Z [neutral] Risk: medium
  On November 14, 2024, Alector, Inc. entered into a material definitive agreement, likely related to its financial obligations. The company also made a regulatio
• SC 13G/A Filing — SC 13G/A · 2024-11-12T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-07T00:00:00.000Z [neutral]
• Alector, Inc. Files Q3 2024 10-Q Report — 10-Q · 2024-11-06T00:00:00.000Z [neutral] Risk: medium
  Alector, Inc. filed its Q3 2024 10-Q report on November 6, 2024, detailing its financial performance and operations for the period ending September 30, 2024. Th
• Alector, Inc. Files Q2 2024 10-Q Report — 10-Q · 2024-08-07T00:00:00.000Z [neutral] Risk: medium
  Alector, Inc. filed its 10-Q for the period ending June 30, 2024, reporting on its financial performance and business operations. The filing details various fin
• Alector, Inc. Files 8-K on Shareholder Vote Matters — 8-K · 2024-06-12T00:00:00.000Z [neutral] Risk: low
  On June 12, 2024, Alector, Inc. filed an 8-K report detailing the submission of matters to a vote of its security holders. The filing indicates that the company
• Alector Files 10-Q: Financials and Partner Updates — 10-Q · 2024-05-08T00:00:00.000Z [neutral] Risk: medium
  Alector, Inc. filed its 10-Q for the period ending March 31, 2024. The company reported its financial position and results of operations. Key financial data inc
• Alector Inc. DEF 14A: Executive Equity Awards Detailed — DEF 14A · 2024-04-25T00:00:00.000Z [neutral] Risk: low
  Alector, Inc. filed a DEF 14A on April 25, 2024, detailing executive compensation and equity awards for the fiscal year ending December 31, 2023. The filing inc
• Alector Appoints New CSO, Elects Director — 8-K · 2024-03-21T00:00:00.000Z [neutral] Risk: medium
  Alector, Inc. announced on March 15, 2024, the appointment of Dr. Arnon Rosenthal as Chief Scientific Officer and the election of Dr. Sarah Hough as a new Class
• Alector's 2023 10-K Highlights R&D Focus and Facility Locations — 10-K · 2024-02-27T00:00:00.000Z [neutral] Risk: high
  Alector, Inc. filed its 10-K for the fiscal year ended December 31, 2023, on February 27, 2024. The filing indicates the company's focus on biological products
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• Morgan Stanley Discloses Passive Stake in Alector (ALEC) — SC 13G · 2024-02-12T00:00:00.000Z [neutral] Risk: low
  Morgan Stanley, a major financial institution, reported its holdings in Alector, Inc. (ALEC) as of December 31, 2023, through an SC 13G filing. This filing indi
• Polaris Ventures Reduces Alector Stake; No Longer Significant Holder — SC 13G/A · 2024-02-09T00:00:00.000Z [bearish] Risk: medium
  Polaris Venture Partners VI, L.P. filed an amended Schedule 13G/A for Alector, Inc. on February 9, 2024, indicating a change in their beneficial ownership as of
• FMR LLC & Abigail Johnson Maintain 14.999% Stake in Alector Inc. — SC 13G/A · 2024-02-09T00:00:00.000Z [neutral] Risk: low
  FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have filed an amendment to their Schedule 13G, indicating they collectively benef
• Alector Insider Arnon Rosenthal Updates Stock Holdings in SC 13G — SC 13G · 2024-02-08T00:00:00.000Z [neutral] Risk: low
  Arnon Rosenthal, a key individual associated with Alector, Inc., filed an Amendment No. 2 to his SC 13G on February 8, 2024, indicating his beneficial ownership
• BlackRock Amends Alector Stake, Maintains Passive Position — SC 13G/A · 2024-01-24T00:00:00.000Z [neutral]
  BlackRock Inc. filed an amended SC 13G/A on January 24, 2024, disclosing its ownership in Alector, Inc. as of December 31, 2023. This filing, Amendment No. 3, i
• Alector Files 8-K on Material Agreement; Details Undisclosed — 8-K · 2024-01-19T00:00:00.000Z [mixed]
  Alector, Inc. filed an 8-K on January 19, 2024, reporting an event that occurred on January 17, 2024, related to an "Entry into a Material Definitive Agreement"
• Alector Files 8-K on Financial Condition, Operations — 8-K · 2024-01-16T00:00:00.000Z [neutral]
  Alector, Inc. filed an 8-K on January 16, 2024, to report on its 'Results of Operations and Financial Condition.' This filing indicates that the company is prov